PortfoliosLab logoPortfoliosLab logo
STOK vs. CELH
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

STOK vs. CELH - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Stoke Therapeutics, Inc. (STOK) and Celsius Holdings, Inc. (CELH). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

STOK vs. CELH - Yearly Performance Comparison


2026 (YTD)2025202420232022202120202019
STOK
Stoke Therapeutics, Inc.
2.58%187.76%109.70%-43.01%-61.53%-61.26%118.68%10.75%
CELH
Celsius Holdings, Inc.
-22.43%73.65%-51.69%57.21%39.52%48.22%941.61%18.38%

Fundamentals

EPS

STOK:

$0.69

CELH:

$0.66

PE Ratio

STOK:

46.94

CELH:

54.08

PS Ratio

STOK:

9.26

CELH:

2.23

Total Revenue (TTM)

STOK:

$205.63M

CELH:

$2.52B

Gross Profit (TTM)

STOK:

$204.64M

CELH:

$1.27B

EBITDA (TTM)

STOK:

$33.10M

CELH:

$171.79M

Returns By Period

In the year-to-date period, STOK achieves a 2.58% return, which is significantly higher than CELH's -22.43% return.


STOK

1D
2.49%
1M
-10.57%
YTD
2.58%
6M
38.55%
1Y
389.62%
3Y*
57.52%
5Y*
-3.71%
10Y*

CELH

1D
4.94%
1M
-33.82%
YTD
-22.43%
6M
-38.28%
1Y
-0.39%
3Y*
4.62%
5Y*
16.52%
10Y*
47.87%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

STOK vs. CELH — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

STOK
STOK Risk / Return Rank: 9898
Overall Rank
STOK Sharpe Ratio Rank: 9999
Sharpe Ratio Rank
STOK Sortino Ratio Rank: 9898
Sortino Ratio Rank
STOK Omega Ratio Rank: 9797
Omega Ratio Rank
STOK Calmar Ratio Rank: 9898
Calmar Ratio Rank
STOK Martin Ratio Rank: 9999
Martin Ratio Rank

CELH
CELH Risk / Return Rank: 4343
Overall Rank
CELH Sharpe Ratio Rank: 4141
Sharpe Ratio Rank
CELH Sortino Ratio Rank: 4040
Sortino Ratio Rank
CELH Omega Ratio Rank: 4040
Omega Ratio Rank
CELH Calmar Ratio Rank: 4545
Calmar Ratio Rank
CELH Martin Ratio Rank: 4646
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

STOK vs. CELH - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Stoke Therapeutics, Inc. (STOK) and Celsius Holdings, Inc. (CELH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


STOKCELHDifference

Sharpe ratio

Return per unit of total volatility

5.66

-0.01

+5.67

Sortino ratio

Return per unit of downside risk

4.72

0.38

+4.34

Omega ratio

Gain probability vs. loss probability

1.61

1.05

+0.56

Calmar ratio

Return relative to maximum drawdown

9.46

0.11

+9.35

Martin ratio

Return relative to average drawdown

33.64

0.27

+33.37

STOK vs. CELH - Sharpe Ratio Comparison

The current STOK Sharpe Ratio is 5.66, which is higher than the CELH Sharpe Ratio of -0.01. The chart below compares the historical Sharpe Ratios of STOK and CELH, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


STOKCELHDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

5.66

-0.01

+5.67

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.05

0.25

-0.30

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.71

Sharpe Ratio (All Time)

Calculated using the full available price history

0.04

0.71

-0.66

Correlation

The correlation between STOK and CELH is 0.22, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

STOK vs. CELH - Dividend Comparison

Neither STOK nor CELH has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

STOK vs. CELH - Drawdown Comparison

The maximum STOK drawdown since its inception was -95.17%, which is greater than CELH's maximum drawdown of -77.86%. Use the drawdown chart below to compare losses from any high point for STOK and CELH.


Loading graphics...

Drawdown Indicators


STOKCELHDifference

Max Drawdown

Largest peak-to-trough decline

-95.17%

-77.86%

-17.31%

Max Drawdown (1Y)

Largest decline over 1 year

-37.16%

-47.87%

+10.71%

Max Drawdown (5Y)

Largest decline over 5 years

-91.80%

-77.86%

-13.94%

Max Drawdown (10Y)

Largest decline over 10 years

-77.86%

Current Drawdown

Current decline from peak

-53.36%

-63.08%

+9.72%

Average Drawdown

Average peak-to-trough decline

-62.55%

-27.15%

-35.40%

Ulcer Index

Depth and duration of drawdowns from previous peaks

10.45%

19.80%

-9.35%

Volatility

STOK vs. CELH - Volatility Comparison

Stoke Therapeutics, Inc. (STOK) has a higher volatility of 20.33% compared to Celsius Holdings, Inc. (CELH) at 15.52%. This indicates that STOK's price experiences larger fluctuations and is considered to be riskier than CELH based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


STOKCELHDifference

Volatility (1M)

Calculated over the trailing 1-month period

20.33%

15.52%

+4.81%

Volatility (6M)

Calculated over the trailing 6-month period

50.97%

45.17%

+5.80%

Volatility (1Y)

Calculated over the trailing 1-year period

69.93%

55.12%

+14.81%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

81.13%

66.64%

+14.49%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

81.20%

68.76%

+12.44%

Financials

STOK vs. CELH - Financials Comparison

This section allows you to compare key financial metrics between Stoke Therapeutics, Inc. and Celsius Holdings, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00200.00M400.00M600.00M800.00MAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
10.63M
721.63M
(STOK) Total Revenue
(CELH) Total Revenue
Values in USD except per share items